1. Remis RS, Alary M, Liu J, Kaul R, Palmer RWH. HIV transmission among men who have sex with men due to condom failure. PLOS ONE 2014; 9: e107540.

2. ACSA. Clinical Supervision: A Working Definition. ACSA Definitions Report. Forest Lake, Qld, 2014.

3. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. New Engl J Med 1997; 337: 1485-1490.

4. Irvine C, Egan KJ, Shubber Z, et al. Efficacy of HIV postexposure prophylaxis: systematic review and meta-analysis of nonhuman primate studies. CID 2015; 60: S165-S169.

5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New Engl J Med 1994; 331: 1173-1180.

6. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006. AIDS 2008; 22: 973–981.

7. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med 2011; 365: 493-505

8. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Engl J Med 2010; 363: 2587-2599.

9. Baeten JM, Donnell D, Ndase P, et al. Antriretroviral prophylaxis in heterosexual men and women. New Engl J Med 2012; 367: 399 – 410.

10. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.

11. Australian Government Department of Health and Ageing. National guidelines for post-exposure prophylaxis after non-occupational exposure to HIV. Available at: https://pep.guidelines.org.au/ (accessed 13 June 2024).

12. Roland ME, Neilands TB, Krone M, et al. Seroconversion following non-occupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41: 1507-1513.

13. Jochimsen EM, Luo CC, Beltrami JF, et al. Investigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virus. Arch Intern Med 1999; 159: 2361-2363.

14. Tsai C-C, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998; 72: 4265-73.

15. Ford N, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS 2014; 28: 2721 – 2727.

16. Ford N & Mayer KH for the World Health Organization. Postexposure prophylaxis guideline development group. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. CID 2015; 60: S161 – S163

17. Post-exposure prophylaxis to prevent HIV infection. Joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection Geneva, Switzerland. WHO, 2007. Available at: http://www.who.int/hiv/pub/prophylaxis/pep_guidelines/en/ (accessed 25 April 2018)

18. McAllister J, Read P, McNulty A, Tong WWY and Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence. HIV Med 2014; 1: 13-22

19. Foster R, McAllister J, Read TR, et al. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure in Men Who Have Sex With Men. Clin Infect Dis 2015; Jun 29. pii: civ511. [Epub ahead of print]

20. McAllister J, Towns J, McNulty A et al. Dolutegravir with tenofovir disoproxil fumarate-emtricitabine as HIV post-exposure prophylaxis in gay and bisexual men [abstract]. In: Proceedings of 21st International AIDS Conference; 2016 Jul 18-22; Durban, South Africa: Abstract WEPEC231

21. Poynten IM, Jin F, Mao L, et al. Nonoccupational postexposure prophylaxis, subsequent risk behaviour and HIV incidence in a cohort of Australian homosexual men. AIDS 2009; 23: 1119-1126.

22. Johnson WD, Diaz RM, Flanders WD, et al. Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men. Cochrane Database Syst Rev 2008: 3: CD001230. doi: 10.1002/14651858.CD001230.pub2.

23. Zablotska IB, Kippax, S, Grulich A, Holt M, Prestage G. Behavioural surveillance among gay men in Australia: methods, findings and policy implications for the prevention of HIV and other sexually transmissible infections. Sexual; Health 2011; 8: 272 – 279.

24. Haberer J. Current Concepts for PrEP Adherence in the PrEP Revolution; from clinical trials to routine practice. Curr Opin HIV AIDS. 2016;1:10–17.

25. The Kirby Institute. Monitoring HIV pre-exposure prophylaxis (PrEP) uptake in Australia. Issue #10, May 2024. Available at https://www.kirby.unsw.edu.au/sites/default/files/documents/Monitoring-HIV-pre-exposure-prohpylaxis-PrEP-uptake-in-Australia_Issue-10.pdf (Accessed 11 June 2024)

26. Australian National PrEP Guidelines. Available at https://prepguidelines.com.au/ (accessed 13 June 2024).

27. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and metaanalysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.

28. McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51:937-46.

29. McAllister J, Morris D, Holliday S, Carr A. Substantial loss of bone mineral density in some patients receiving tenofovir-emtricitabine as HIV pre-exposure prophylaxis [abstract]. In 18th International Workshop on Comorbidities and Adverse Drug Reactions in HIV; 2016 Sep 12-13; New York: Abstract 002.

30. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090.